ACADIA Pharmaceuticals Inc
NASDAQ:ACAD
ACADIA Pharmaceuticals Inc
ACADIA Pharmaceuticals Inc., nestled in the heart of biopharmaceutical innovation, has carved a niche as a trailblazer in tackling neurological and central nervous system disorders. The company's journey pivotally surrounds its flagship product, NUPLAZID (pimavanserin), which was approved by the FDA in 2016. Designed to address the psychosis associated with Parkinson’s disease, NUPLAZID opened new therapeutic doors, addressing a critical unmet medical need and improving patients’ quality of life. Leveraging this milestone, ACADIA has strategically focused on developing innovative therapies, extending its research into potential treatments for schizophrenia, major depressive disorders, and other neuropsychiatric conditions, thus widening its revenue streams and research portfolios.
The company's financial engine is fueled primarily by sales of NUPLAZID, which has stood as a steady pillar in generating revenues. To amplify its growth trajectory, ACADIA emphasizes expanding NUPLAZID's usability through rigorous clinical trials aimed at securing approvals for additional indications. Concurrently, the company actively explores partnerships and acquisitions to broaden its pipeline, inaugurating an aspirational pursuit to revolutionize mental health treatment. With a keen eye on demographic trends and the increasing prevalence of CNS disorders globally, ACADIA Pharmaceuticals aligns its business operations not just on curing ailments, but on redefining health paradigms, thus reinforcing its sustainability in the competitive biopharmaceutical landscape.
ACADIA Pharmaceuticals Inc., nestled in the heart of biopharmaceutical innovation, has carved a niche as a trailblazer in tackling neurological and central nervous system disorders. The company's journey pivotally surrounds its flagship product, NUPLAZID (pimavanserin), which was approved by the FDA in 2016. Designed to address the psychosis associated with Parkinson’s disease, NUPLAZID opened new therapeutic doors, addressing a critical unmet medical need and improving patients’ quality of life. Leveraging this milestone, ACADIA has strategically focused on developing innovative therapies, extending its research into potential treatments for schizophrenia, major depressive disorders, and other neuropsychiatric conditions, thus widening its revenue streams and research portfolios.
The company's financial engine is fueled primarily by sales of NUPLAZID, which has stood as a steady pillar in generating revenues. To amplify its growth trajectory, ACADIA emphasizes expanding NUPLAZID's usability through rigorous clinical trials aimed at securing approvals for additional indications. Concurrently, the company actively explores partnerships and acquisitions to broaden its pipeline, inaugurating an aspirational pursuit to revolutionize mental health treatment. With a keen eye on demographic trends and the increasing prevalence of CNS disorders globally, ACADIA Pharmaceuticals aligns its business operations not just on curing ailments, but on redefining health paradigms, thus reinforcing its sustainability in the competitive biopharmaceutical landscape.
Record Revenue: ACADIA's annual revenues surpassed $1 billion for the first time, reaching $1.08 billion in 2025, a 14% increase over last year.
Q4 Growth: Adjusted total revenues in Q4 were $298 million, up 16% year-over-year, with strong performance from both NUPLAZID and DAYBUE.
NUPLAZID Momentum: Adjusted NUPLAZID net sales rose to $189 million for Q4 (up 17% YoY), and are guided to grow 10–14% in 2026, aiming for $1 billion in annual sales by 2028.
DAYBUE Outlook: DAYBUE Q4 sales reached $110 million (up 13% YoY), with 2026 global net sales guidance of $460–490 million, reflecting 18–25% projected growth.
New Formulation Launch: DAYBUE STIX, a powder formulation, launched in December and is generating strong early interest from caregivers and physicians.
EU Regulatory Setback: DAYBUE's EU approval faces a negative opinion; ACADIA plans to request reexamination, with a decision expected by mid-2026.
Pipeline Progress: Key clinical readouts for remlifanserin, targeting Alzheimer’s disease psychosis, are expected in August–October 2026, with peak sales potential of $4 billion for ADP and LBDP indications.
Strong Cash Position: ACADIA ended the year with $820 million in cash, providing flexibility for business development and R&D investment.
